Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul;52(1):54-69.
doi: 10.1002/jmri.26907. Epub 2019 Aug 27.

Imaging signatures of glioblastoma molecular characteristics: A radiogenomics review

Affiliations
Review

Imaging signatures of glioblastoma molecular characteristics: A radiogenomics review

Anahita Fathi Kazerooni et al. J Magn Reson Imaging. 2020 Jul.

Abstract

Over the past few decades, the advent and development of genomic assessment methods and computational approaches have raised the hopes for identifying therapeutic targets that may aid in the treatment of glioblastoma. However, the targeted therapies have barely been successful in their effort to cure glioblastoma patients, leaving them with a grim prognosis. Glioblastoma exhibits high heterogeneity, both spatially and temporally. The existence of different genetic subpopulations in glioblastoma allows this tumor to adapt itself to environmental forces. Therefore, patients with glioblastoma respond poorly to the prescribed therapies, as treatments are directed towards the whole tumor and not to the specific genetic subregions. Genomic alterations within the tumor develop distinct radiographic phenotypes. In this regard, MRI plays a key role in characterizing molecular signatures of glioblastoma, based on regional variations and phenotypic presentation of the tumor. Radiogenomics has emerged as a (relatively) new field of research to explore the connections between genetic alterations and imaging features. Radiogenomics offers numerous advantages, including noninvasive and global assessment of the tumor and its response to therapies. In this review, we summarize the potential role of radiogenomic techniques to stratify patients according to their specific tumor characteristics with the goal of designing patient-specific therapies. Level of Evidence: 5 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2020;52:54-69.

Keywords: glioblastoma; machine learning; magnetic resonance imaging; molecular signatures; radiogenomics; radiomics.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
A representation of the proper workflow of a radiomic study, which includes the following steps: 1) image acquisition, 2) image processing, including noise/artifact reduction, intensity and/or orientation standardization, co-registration of the multi-parametric MRI scans, 3) region-of-interest definition using manual annotation or (semi-)automatic segmentation, 4) feature extraction based on human-engineered (conventional radiomics) or deep learning approaches, and 5) data analysis, involving machine/deep learning methods for feature selection, classification, and cross-validation. Radiogenomics studies should ideally follow the same workflow, with genomics of glioblastoma as their endpoint.
Fig. 2.
Fig. 2.
An illustration of descriptive characteristics of mutant EGFRvIII (EGFRvIII+) tumors (adopted from ref. (104) with permission from the authors and the publisher (Oxford University Press, License No. 4636511399697)).

References

    1. Davis ME. Glioblastoma: overview of disease and treatment. Clinical journal of oncology nursing 2016;20(5):S2. - PMC - PubMed
    1. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. Jama 2017;318(23):2306–2316. - PMC - PubMed
    1. Barnholtz-Sloan JS, Ostrom QT, Cote D. Epidemiology of Brain Tumors. Neurologic clinics 2018;36(3):395–419. - PubMed
    1. Wang Y, Jiang T. Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer letters 2013;331(2):139–146. - PubMed
    1. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes & development 2007;21(21):2683–2710. - PubMed

Publication types